PNC Financial Services Group Inc. Has $13.17 Million Position in Zimmer Biomet Holdings, Inc. $ZBH

PNC Financial Services Group Inc. lessened its position in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 9.7% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 145,637 shares of the medical equipment provider’s stock after selling 15,558 shares during the period. PNC Financial Services Group Inc.’s holdings in Zimmer Biomet were worth $13,169,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also added to or reduced their stakes in the company. DV Equities LLC acquired a new position in Zimmer Biomet during the fourth quarter valued at approximately $25,000. Monetary Solutions Ltd acquired a new stake in shares of Zimmer Biomet in the 4th quarter valued at $30,000. Gen Wealth Partners Inc bought a new position in shares of Zimmer Biomet in the 4th quarter valued at $31,000. Flagship Harbor Advisors LLC acquired a new position in shares of Zimmer Biomet during the 4th quarter worth $32,000. Finally, Headlands Technologies LLC acquired a new position in shares of Zimmer Biomet during the 2nd quarter worth $37,000. 88.89% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of research analysts have issued reports on the company. Stifel Nicolaus decreased their target price on Zimmer Biomet from $110.00 to $105.00 and set a “buy” rating on the stock in a research report on Wednesday, April 29th. Barclays dropped their target price on shares of Zimmer Biomet from $100.00 to $94.00 and set an “underweight” rating for the company in a report on Wednesday, April 29th. JPMorgan Chase & Co. reduced their price target on shares of Zimmer Biomet from $100.00 to $95.00 and set a “neutral” rating on the stock in a research note on Wednesday, April 29th. Canaccord Genuity Group set a $83.00 price target on shares of Zimmer Biomet in a report on Wednesday, April 29th. Finally, Leerink Partners began coverage on shares of Zimmer Biomet in a research report on Monday, April 13th. They set a “hold” rating and a $101.00 price objective for the company. One equities research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, twelve have assigned a Hold rating and four have assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Zimmer Biomet currently has a consensus rating of “Hold” and a consensus target price of $100.70.

Insider Activity

In other news, insider Sang Yi sold 5,000 shares of the firm’s stock in a transaction dated Friday, May 29th. The stock was sold at an average price of $82.64, for a total transaction of $413,200.00. Following the completion of the transaction, the insider directly owned 27,251 shares in the company, valued at $2,252,022.64. This trade represents a 15.50% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 1.28% of the stock is owned by company insiders.

Zimmer Biomet Price Performance

Shares of ZBH opened at $91.35 on Friday. The company has a quick ratio of 0.95, a current ratio of 1.73 and a debt-to-equity ratio of 0.50. The stock has a market cap of $17.67 billion, a PE ratio of 23.73, a PEG ratio of 2.69 and a beta of 0.46. Zimmer Biomet Holdings, Inc. has a 12-month low of $79.12 and a 12-month high of $108.29. The business has a 50-day simple moving average of $87.90 and a two-hundred day simple moving average of $89.81.

Zimmer Biomet (NYSE:ZBH) last issued its quarterly earnings data on Tuesday, April 28th. The medical equipment provider reported $2.09 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.86 by $0.23. The business had revenue of $2.09 billion during the quarter, compared to analyst estimates of $2.07 billion. Zimmer Biomet had a net margin of 9.05% and a return on equity of 13.24%. The firm’s quarterly revenue was up 9.3% on a year-over-year basis. During the same quarter last year, the business earned $1.81 EPS. Zimmer Biomet has set its FY 2026 guidance at 8.400-8.550 EPS. Analysts anticipate that Zimmer Biomet Holdings, Inc. will post 8.48 earnings per share for the current fiscal year.

Zimmer Biomet Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, July 31st. Stockholders of record on Thursday, June 25th will be paid a $0.24 dividend. The ex-dividend date of this dividend is Thursday, June 25th. This represents a $0.96 annualized dividend and a dividend yield of 1.1%. Zimmer Biomet’s dividend payout ratio is presently 24.94%.

Zimmer Biomet Company Profile

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.